2019
DOI: 10.18821/0016-9900-2017-96-5-422-426
|View full text |Cite
|
Sign up to set email alerts
|

Valproic Acid as a Reference Substance for the Study of the Molecular-Genetic Mechanism of Obesogenity of Endocrine Disrupters

Abstract: Perfluorooctanoic acid (PFOA) and its derivatives are recognized as obesogens. Clinically used valproic acid (VPA) as a drug is structurally similar to PFOA. The objective of the investigation was to study the molecular-genetic mechanism of the weight gain by patients taking the VPA drugs and correlation with candidate genes involved in the metabolism of medium chain fatty acids. Weight and basal insulin level were evaluated in 238 patients both before and after 12 months of VPA treatment. Genotyping of SNPs r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 12 publications
0
0
0
Order By: Relevance